ERBB2 and cancer: In the I-SPY2 trial, the combination of pembrolizumab with chemotherapy led to a more than doubling of the pCR rate in patients with early stage HR-positive/HER2-negative cancers who had a MammaPrint that was not in the low risk range (21).